{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016905","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.949165+00:00","generated_at":"2026-06-24T00:46:59.786129+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aura Biosciences Q2 2022 net loss $13.5M; cash $122.1M; NMIBC trial on track","bullets":["Net loss $13.5M for Q2 2022 vs $8.9M in Q2 2021; R&D expense rose to $9.5M from $6.6M.","Cash and equivalents $122.1M; sufficient to fund operations into 2024.","On track to dose first patient in Phase 1 NMIBC trial in Q3 2022; FDA Fast Track granted.","On track to initiate pivotal trial in early-stage choroidal melanoma in Q4 2022.","Plans to file IND for choroidal metastases in Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016905","json":"https://secwatch.observer/filing/0000950170-22-016905.json","markdown":"https://secwatch.observer/filing/0000950170-22-016905.md","text":"https://secwatch.observer/filing/0000950170-22-016905.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017022016905/0000950170-22-016905-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017022016905/aura-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:46:59.786129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}